PaulMichaelBarrMD

PubMed

• 93 citations
  Phase II Intergroup Trial of Alisertib in Relapsed and Refractory Peripheral T-Cell Lymphoma and Transformed Mycosis Fungoides: SWOG 1108
  Paul M. Barr, Hongli Li, Catherine M. Spier, Daruka Mahadevan, Michael LeBlanc
  Journal of Clinical Oncology. 2015-06-15
• 119 citations
  Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia.
  Paul M Barr, Carolyn Owen, Tadeusz Robak, Alessandra Tedeschi, Osnat Bairey
  Blood Advances. 2022-06-14
• 6 citations
  Treatment Discontinuation Patterns for Patients With Chronic Lymphocytic Leukemia in Real-World Settings: Results From a Multi-Center International Study.
  Mazyar Shadman, Beenish S Manzoor, Kavita Sail, Hande H Tuncer, John N Allan
  Clinical Lymphoma, Myeloma & Leukemia. 2023-07-01

Journal Articles

• Sustained Efficacy and Detailed Clinical Follow-up of First-Line Ibrutinib Treatment in Older Patients with Chronic Lymphocytic Leukemia: Extended Phase 3 Results from...  
  Steven Coutre, Thomas J Kipps, Jan A Burger, Nancy L Bartlett, Paul M Barr, Haematologica
• Recommendations for Clinical Trial Development in Follicular Lymphoma  
  Maddocks K, Barr PM, Cheson BD, Little RF, Baizer L, Kahl BS, Leonard JP, Fowler N, Gordon LI, Link BK, Friedberg JW, Ansell SM, J Natl Cancer Inst, 1/31/2016
• Prospective Clinicogenetic Risk Models To Predict Early Progression of Follicular Lymphoma after First-Line Immunochemotherapy  
  Jurinovic V; Kridel R; Staiger AM; Szczepanowski M; Horn H; Dreyling MH; Rosenwald A; Ott G; Klapper W; Zelenetz AD; Barr PM; Friedberg JW; Ansell S; Sehn LH; Connors ..., Blood, 1/25/2016
• "US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose-Positron Emission Tomography Imaging: Sout...  
  Press OW; Li H; Schoder H; Straus DJ; Moskowitz CH; LeBlanc M; Rimsza LM; Bartlett NL; Evens AM; Mittra ES; LaCasce AS; Sweetenham JW; Barr PM; Fanale MA; Knopp MV; No..., Journal of Clinical Oncology, 1/10/2016
• "Phase 2 study of idelalisib and entospletinib: pneumonitis limits combination therapy in relapsed refractory CLL and NHL"  
  Barr PM; Saylors GB; Spurgeon SE; Cheson BD; Greenwald DR; O'Brien SM; Liem AK; McIntyre RE; Joshi A; Abella-Dominicis E; Hawkins MJ; Reddy A; Di Paolo J; Lee H; He J;..., Blood, 1/1/2016
• Deregulation of NF-kB, ie, a useful PMBL marker  
  Barr PM, Blood, 1/1/2016
• Prognostic Impact of Cell of Origin in Limited-Stage Diffuse Large B-Cell Lymphoma Treated With R-CHOP With or Without Radiation Therapy  
  Youn P; Cummings MA; Dhakal S; Burack WR; Casulo C; Barr PM; Friedberg JW; Constine LS, International Journal of Radiation Oncology, Biology, Physics, 1/1/2016
• "Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experience"  
  Mato AR; Nabhan C; Barr PM; Ujjani CS; Hill BT; Lamanna N; Skarbnik AP; Howlett C; Pu JJ; Sehgal AR; Strelec LE; Vandegrift A; Fitzpatrick DM; Zent CS; Feldman T; Goy ..., Blood, 1/1/2016
• Survival of Secondary Central Nervous System Lymphoma Patients in the Rituximab Era  
  Herr MM; Mohile NA; Barr PM; van Wijngaarden E; Brown EB; Rich DQ, Clinical Lymphoma, Myeloma & Leukemia, 1/1/2016
• "Phase 1 study of single-agent CC-292, a highly selective Bruton's tyrosine kinase inhibitor, in relapsed or refractory chronic lymphocytic leukemia"  
  Brown JR; Harb WA; Hill BT; Gabrilove J; Sharman JP; Schreeder MT; Barr PM; Foran JM; Miller TP; Burger JA; Kelly KR; Mahadevan D; Ma S; Li Y; Pierce DW; Barnett E; Ma..., Haematologica, 1/1/2016
• Post-ibrutinib outcomes in patients with mantle cell lymphoma  
  Martin P, Maddocks K, Leonard JP, Ruan J, Goy A, Wagner-Johnston N, Rule S, Advani R, Iberri D, Phillips T, Spurgeon S, Kozin E, Noto K, Chen Z, Jurczak W, Auer R, Chm..., Blood, 1/1/2016
• Phase 1 Trial of Carfilzomib (PR-171) in Combination with Vorinostat (SAHA) in Patients with Relapsed or Refractory B-Cell Lymphomas  
  Holkova B, Kmieciak M, Bose P, Yazbeck VY, Barr PM, Tombes MB, Shrader E, Weir-Wiggins C, Rollins AD, Cebula EM, Pierce E, Herr M, Sankala H, Hogan KT, Wan W, FengC , ..., Leukemia and Lymphoma, 1/1/2016
• Phase II intergroup trial of alisertib in relapsed and refractory peripheral T-cell lymphoma and transformed mycosis fungoides: SWOG 1108  
  Barr PM, Li H, Spier C, Mahadevan D, LeBlanc M, Ul Haq M, Huber BD, Flowers CR, Wagner-Johnston ND, Horwitz SM, Fisher RI, Cheson BD, Smith SM, Kahl BS, Bartlett NL, F..., Journal of Clinical Oncology, 1/20/2015
• "Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia"  
  Burger JA, Tedeschi A, Barr PM, Robak T, Owen C, Ghia P, Bairey O, Hillmen P, Bartlett NL, Li J, Simpson D, Grosicki S, Devereux S, McCarthy H, Coutre S, Quach H, Gaid..., The New England Journal of Medicine, 1/17/2015
• The Bruton's tyrosine kinase inhibitor, ibrutinib, with chemoimmunotherapy in patients with chronic lymphocytic leukemia  
  Brown JR, Barrientos JC, Barr PM, Flinn IW, Burger JA, Tran A, Clow F, James DF, Graef T, Friedberg JF, Rai K, O'Brien S, Blood, 1/7/2015
• Rituximab maintenance in follicular lymphoma  
  Barr PM, Clinical Advances In Hematology & Oncology, 1/1/2015
• Recent advances in the development of Aurora kinase inhibitors in hematological malignancies  
  Choudary I, Barr PM, Friedberg J, Therapeutic Advances in Hematology, 1/1/2015
• Targeting B Cell Receptor Signaling with Ibrutinib in Diffuse Large B Cell Lymphoma  
  Wilson WH, Young RM, Schmitz R, Yang Y, Pittaluga S, Wright G, Lih CJ, Williams PM, Shaffer AL, Gerecitano J, de Vos S, Goy A, Kenkre VP, Barr PM, Blum KA, Shustov A, ..., Nature Medicine, 1/1/2015
• Attempting to avoid chemotherapy in CLL with lenalidomide and rituximab  
  Barr PM, Journal of Clinical Oncology, 1/27/2014
• Infection in chronic lymphocytic leukemia: parsimony has its limits  
  Barr PM, Zent CS, Leukemia & Lymphoma, 1/25/2014
• Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia  
  Byrd JC, Brown JR, O'Brien S, Barrientos JC, Kay NE, Reddy NM, Coutre S, Tam CS, Mulligan SP, Jaeger U, Devereux S, Barr PM, Furman RR, Kipps TJ, Cymbalista F, Pocock ..., The New England Journal of Medicine, 1/17/2014
• Impact of dietary supplements, obesity, and treatment initiation on serum vitamin D levels in lymphoma patients  
  Hutchinson K, Jahangiri S, Calvi LM, Barr PM, Friedberg JW, Kelly JL, Leukemia & Lymphoma, 1/15/2014
• Crizotinib as Salvage and Maintenance with Allogeneic Stem Cell Transplantation for Refractory Anaplastic Large Cell Lymphoma  
  Cleary JM, Rodig S, Barr PM, Shinagare AB, Clark J, Shaprio GI, Armand P, Journal of the National Comprehensive Cancer Network, 1/1/2014
• The ABC of CLL: Etiology of Cytopenias is Important in Staging and Management  
  Barr PM, Zent CS, Leukemia & Lymphoma, 1/1/2014
• Emerging protein kinase inhibitors for the treatment of non-Hodgkin's lymphoma  
  Jahangiri S, Friedberg J, Barr PM, Expert Opinion on Emerging Drugs, 1/1/2014
• Join now to see all

Books/Book Chapters

• Rare Lymphomas 
  Chapter: Adult Burkitt Lymphoma and Leukemia. 
  Page 171 - 194Gokbuget N, Barr PM, Friedberg JW, Hsi ED, Ott GEditors: Dreyling M.Springer-Verlag Berlin Heidelberg, New York2014
• Textbook of Uncommon Cancers 
  Chapter: Rare B Cell Lymphoproliferative Disorders. 
  Barr PM, Friedberg JWEditors: Sekkeres MA.Wiley-Blackwell, Oxford, EnglandEdition 4th,2012
• Adult Acute Lymphocytic Leukemia: Biology and Treatment 
  Chapter: Pharmacology of Acute Lymphoblastic Leukemia Therapy. 
  Barr PM, Creger RJ, Berger NAEditors: Advani A, Lazarus HM.Humana Press, New York, NY2010
• Cancer, Principles & Practice of Oncology 
  Chapter: Non-Hodgkin lymphomas. 
  Barr PMEditors: Devita VT, Lawrence TS, Rosenberg SA.Lippincott Williams & WilkinsEdition 9th,2008
• Join now to see all

Abstracts/Posters

• Treatment Sequences and Outcomes of Patients with CLL Treated with Venetoclax and Other Novel Agents Post Introduction of Novel Therapies
  Paul M. Barr, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Treatment Discontinuation Patterns for Patients with CLL in the Real-World Settings: Results from a Multi-Center Study
  Paul M. Barr, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Efficacy of Therapies Following Venetoclax Discontinuation in CLL: Focus on B-Cell Receptor Signal Transduction Inhibitors and Cellular Therapies
  Paul M. Barr, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Ibrutinib and Rituximab Provides Superior Clinical Outcome Compared to FCR in Younger Patients with Chronic Lymphocytic Leukemia (CLL): Extended Follow-up from the E19...
  Paul M. Barr, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Anti-CD20 Therapy Reliance on Antibody-Dependent Cellular Phagocytosis Affects Combination Drug Choice
  Paul M. Barr, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Using Ibrutinib in Earlier Lines of Treatment Results in Better Outcomes for Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
  Paul M. Barr, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Utilization and Early Discontinuation of First-Line Ibrutinib for Patients with Chronic Lymphocytic Leukemia Treated in the Community Oncology Setting in the United St...
  Paul M. Barr, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• A Pilot Study of Brentuximab Vedotin Combined with AVD Chemotherapy and Radiotherapy in Patients with Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma
  Paul M. Barr, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Ibrutinib (Ibr) Plus Venetoclax (Ven) for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Results from the MRD Cohort of t...
  Paul M. Barr, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Treatment Sequences and Outcomes of Patients with CLL Treated with Venetoclax and Other Novel Agents Post Introduction of Novel Therapies
  Paul M. Barr, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• PET-Directed Therapy for Patients with Limited-Stage Diffuse Large B-Cell Lymphoma - Results of Intergroup Nctn Study S1001
  Paul M. Barr, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• "Phase II Study of RCHOP, Consolidative RIT and Maintenance Rituximab: 5-year results of S0801"
  Barr PM, American Society of Hematology Annual Meeting, San Diego, CA, 1/5/2016
• "Updated Efficacy and Safety from the Phase 3 RESONATE-2™ Study: Ibrutinib as First-Line Treatment Option in Patients 65 Years and Older With Chronic Lymphocytic Leuke...
  Barr PM, American Society of Hematology Annual Meeting, San Diego, CA, 1/3/2016
• Join now to see all

Lectures

• Final analysis from RESONATE: Six-year follow-up in patients (pts) with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) on ibru... 
  2019 ASCO Annual Meeting - 6/1/2019
• Nivolumab Combined with Brentuximab Vedotin for Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma: Preliminary Results from the Phase 2 CheckMate 436 Trial 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Five-Year Outcomes of SWOG S0: A Randomized Phase II US Intergroup Study of R-HCVAD Vs. R-Bendamustine Followed By Autologous Stem Cell Transplant for Patients with Ma... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Acalabrutinib combined with PI3K inhibitor ACP-319 in patients (pts) with relapsed/refractory (R/R) B-cell malignancies. 
  2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
• "Indolent non-Hodgkin lymphoma" 
  Cleveland, OH - 1/21/2016
• "Surviving FDA inspections" 
  Chicago, IL - 1/21/2016
• "Changing Clinical Trial Designs" 
  1/18/2016
• "Future Applications of Idelalisib" 
  Whistler, British Columbia, Canada - 1/3/2016
• "Lymphoma Overview" 
  Rochester, NY - 1/2/2016
• "Optimal Management of Deletion 17p CLL: Novel Agents" 
  New York, NY - 1/1/2016
• "Abbvie CLL day-Current diagnosis and management of CLL" 
  1/26/2015
• "Chronic Lymphocytic Leukemia" 
  San Diego, CA - 1/23/2015
• "Changing Treatment Paradigms in Lymphoma and CLL-2014 ASH update" 
  Rochester, NY - 1/18/2015
• "PI3K and Syk Inhibition Limited by Pneumonitis; Results of a Phase II Trial" 
  Lugano, Switzerland - 1/16/2015
• "Building on B-cell receptor signaling in chronic lymphocytic leukemia" 
  Rochester, NY - 1/12/2015
• "Lymphoma Education and Advocacy Partners Webinar-Advocacy for Lymphoma Clinical Trials" 
  1/2/2015
• "Syk inhibition in CLL" 
  Whistler, British Columbia, Canada - 1/27/2014
• "Targeting Aurora Kinase in Peripheral T cell Lymphoma" 
  San Francisco, CA - 1/25/2014
• "Return on Investments in Clinical Research" 
  Chicago, IL - 1/10/2014
• "Protein Kinase Inhibition in Peripheral T-cell Lymphoma" 
  San Francisco, CA - 1/6/2014
• "Special Considerations for TP53 Dysfunction in CLL" 
  New York, NY - 1/1/2014
• "CLL; Management in the current era" 
  Rochester, NY - 1/30/2013
• "Diffuse large B cell lymphoma; Current Research Initiatives" 
  Cornell Veterinary School, Ithaca, NY - 1/20/2013
• "Research and Clinical Trials" 
  University of Rochester, Rochester, NY - 1/14/2013
• "Changing Paradigms in Hematologic Malignancies" 
  University of Rochester - 1/13/2013
• Join now to see all

Other

• Clinical evaluation and management of Burkitt Lymphoma 
  Barr PM, Friedberg JW, Clinical Decision Support in Hematology, 1st Edition
  1/1/2013
• Non-Hodgkin Lymphoma. 
  Barr PM and Fisher RI, Clinical Care Options in Practice (Govindan R, Kantarjian H.(eds)
  1/1/2009